Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275767 | 0.81 | NPSR1 (0.50) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD | |
| SCHEMBL794531 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD | |
| SCHEMBL2632700 | 0.81 | NPSR1 (0.50) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD | |
| SCHEMBL11917066 | 0.79 | NPSR1 (0.48) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD | |
| SCHEMBL23412984 | 0.79 | KDM4E (0.55) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD | |
| SCHEMBL1549089 | 0.79 | ALDH1A1 (0.54) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD | |
| SCHEMBL3046694 | 0.79 | KDM4E (0.59) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD | |
| SCHEMBL2476214 | 0.79 | ALDH1A1 (0.54) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD | |
| SCHEMBL7944932 | 0.77 | NPSR1 (0.45) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD | |
| SCHEMBL2442460 | 0.77 | ALDH1A1 (0.51) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288429-B2 | 2-aza-bicyclo[3.3.0]octane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288411-B2 | Pyrrolidines and piperidines as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288411-B2 | Pyrrolidines and piperidines as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288435-B2 | 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288429-B2 | 2-aza-bicyclo[3.3.0]octane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8236801-B2 | 2-aza-bicyclo[2.2.1]heptane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8063099-B2 | Trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110009461-A1 | 2-AZA-BICYCLO[3.3.0]OCTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-13 | — | — | US | disclosed |
| US-20110009461-A1 | 2-AZA-BICYCLO[3.3.0]OCTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2155739-B1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100197733-A1 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-05 | — | — | US | disclosed |
| US-20100197733-A1 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-05 | — | — | US | disclosed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | disclosed |
| WO-2009040730-A2 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009016564-A2 | 2-AZA-BICYCLO[3.3.0]OCTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008139416-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197733-A1 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | ALDH1A1 1350/4885KDM4E 1763/4885HSD17B10 4476/4885 |
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | ALDH1A1 747/4885KDM4E 1778/4885HSD17B10 1686/4885 |
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CNR1 | ALDH1A1 807/4885KDM4E 1064/4885HSD17B10 1850/4885 |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | ALDH1A1 702/4885KDM4E 735/4885HSD17B10 1770/4885 |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | HCRTR2, HCRTR1, NPY2R | ALDH1A1 937/4885KDM4E 2641/4885HSD17B10 2091/4885 |
| US-20110009461-A1 | 2-AZA-BICYCLO[3.3.0]OCTANE DERIVATIVES | HCRTR2, HCRTR1, NPY2R | ALDH1A1 624/4885KDM4E 702/4885HSD17B10 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.